Methods of treating breast cancer with tetrahydronaphthalene derivatives as estrogen receptor degraders

US12208095B2 · kind B2 · utility

Assignee

• Arvinas Operations, Inc. · US

Inventors

• Andrew P. Crew · Farmingdale, US
• John Flanagan · Berkeley, US
• Sheryl Maxine GOUGH · Stratford, US
• Royal J. HASKELL, III · Durham, US
• Marcia Dougan MOORE · Suffield, US
• Yimin Qian · Plainsboro, US
• Ian Charles Anthony TAYLOR · Madison, US
• Jing Wang · Milford, US

Key dates

• Filing date: Aug 24, 2020
• Grant date: Jan 28, 2025
• Expiry date: Aug 24, 2040

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present application relates to treating and/or preventing breast cancer, including locally advanced or metastatic, ER+, HER2− breast cancer, in a subject in need of treatment, comprising administering a compound of Formula (I), or a pharmaceutically acceptable salt, enantiomer, stereoisomer, solvate, polymorph, isotopic derivative, or prodrug thereof, wherein R1, R2, R3, R4, m, and n are defined herein.